PubMed:9736046 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":106},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":107,"end":227},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":228,"end":371},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":372,"end":432},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":433,"end":559},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":560,"end":613},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":614,"end":661},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":662,"end":704},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":705,"end":934},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":935,"end":977},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":978,"end":1142},"obj":"Sentence"},{"id":"TextSentencer_T12","span":{"begin":1143,"end":1328},"obj":"Sentence"},{"id":"TextSentencer_T13","span":{"begin":1329,"end":1576},"obj":"Sentence"},{"id":"TextSentencer_T14","span":{"begin":1577,"end":1693},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":106},"obj":"Sentence"},{"id":"T2","span":{"begin":107,"end":227},"obj":"Sentence"},{"id":"T3","span":{"begin":228,"end":371},"obj":"Sentence"},{"id":"T4","span":{"begin":372,"end":432},"obj":"Sentence"},{"id":"T5","span":{"begin":433,"end":559},"obj":"Sentence"},{"id":"T6","span":{"begin":560,"end":613},"obj":"Sentence"},{"id":"T7","span":{"begin":614,"end":661},"obj":"Sentence"},{"id":"T8","span":{"begin":662,"end":704},"obj":"Sentence"},{"id":"T9","span":{"begin":705,"end":934},"obj":"Sentence"},{"id":"T10","span":{"begin":935,"end":977},"obj":"Sentence"},{"id":"T11","span":{"begin":978,"end":1142},"obj":"Sentence"},{"id":"T12","span":{"begin":1143,"end":1328},"obj":"Sentence"},{"id":"T13","span":{"begin":1329,"end":1576},"obj":"Sentence"},{"id":"T14","span":{"begin":1577,"end":1693},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.\nMRP-1/CD9, KAI1/CD82, and ME491/CD63, have been reported to be associated with the metastatic potential of solid tumors. The aim of this study was to determine whether their expression in tumor tissues is a useful indicator for prognosis in breast cancer patients. We studied 109 breast cancer patients who underwent surgery. Quantitative reverse transcription-polymerase chain reaction analysis was performed to evaluate the expression of these genes. The results were confirmed with immunohistochemistry. All of the carcinomas were ME491/CD63 positive. Thirty-six tumors were MRP-1/CD9 negative. The disease-free survival rate and the 5-year survival rate of patients with MRP-1/CD9-negative tumors were both significantly lower than that in patients with MRP-1/ CD9-positive tumors (P = 0.0005 and P = 0.0380, respectively). Sixty-five tumors were KAI1/CD82 negative. The disease-free survival rate of patients with KAI1/CD82-negative tumors was significantly lower than that of patients with KAI1/CD82-positive tumors (P = 0.0065). Cox regression analysis demonstrated that MRP-1/CD9 status (P = 0.0016) and KAI1/CD82 status (P = 0.0234) were useful indicators for the disease-free survival of breast cancer patients. The disease-free survival rate and 5-year survival rate of patients with either MRP-1/CD9-negative or KAI1/CD82-negative tumors were both significantly lower than patients who were positive for both genes (P = 0.0003 and P = 0.0292, respectively). The expression of MRP-1/CD9 and KAI1/CD82 genes are useful indicators of a poor prognosis in breast cancer patients."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":47,"end":51},"obj":"gene:3732"},{"id":"T1","span":{"begin":83,"end":96},"obj":"disease:C0678222"},{"id":"T2","span":{"begin":47,"end":51},"obj":"gene:3732"},{"id":"T3","span":{"begin":83,"end":96},"obj":"disease:C0006142"},{"id":"T4","span":{"begin":139,"end":143},"obj":"gene:967"},{"id":"T5","span":{"begin":214,"end":226},"obj":"disease:C0280100"},{"id":"T6","span":{"begin":133,"end":138},"obj":"gene:967"},{"id":"T7","span":{"begin":214,"end":226},"obj":"disease:C0280100"},{"id":"T8","span":{"begin":123,"end":127},"obj":"gene:3732"},{"id":"T9","span":{"begin":214,"end":226},"obj":"disease:C0280100"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"},{"id":"R5","pred":"associated_with","subj":"T8","obj":"T9"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.\nMRP-1/CD9, KAI1/CD82, and ME491/CD63, have been reported to be associated with the metastatic potential of solid tumors. The aim of this study was to determine whether their expression in tumor tissues is a useful indicator for prognosis in breast cancer patients. We studied 109 breast cancer patients who underwent surgery. Quantitative reverse transcription-polymerase chain reaction analysis was performed to evaluate the expression of these genes. The results were confirmed with immunohistochemistry. All of the carcinomas were ME491/CD63 positive. Thirty-six tumors were MRP-1/CD9 negative. The disease-free survival rate and the 5-year survival rate of patients with MRP-1/CD9-negative tumors were both significantly lower than that in patients with MRP-1/ CD9-positive tumors (P = 0.0005 and P = 0.0380, respectively). Sixty-five tumors were KAI1/CD82 negative. The disease-free survival rate of patients with KAI1/CD82-negative tumors was significantly lower than that of patients with KAI1/CD82-positive tumors (P = 0.0065). Cox regression analysis demonstrated that MRP-1/CD9 status (P = 0.0016) and KAI1/CD82 status (P = 0.0234) were useful indicators for the disease-free survival of breast cancer patients. The disease-free survival rate and 5-year survival rate of patients with either MRP-1/CD9-negative or KAI1/CD82-negative tumors were both significantly lower than patients who were positive for both genes (P = 0.0003 and P = 0.0292, respectively). The expression of MRP-1/CD9 and KAI1/CD82 genes are useful indicators of a poor prognosis in breast cancer patients."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"9736046-1#16#20#gene3732","span":{"begin":123,"end":127},"obj":"gene3732"},{"id":"9736046-1#26#31#gene967","span":{"begin":133,"end":138},"obj":"gene967"},{"id":"9736046-1#32#36#gene967","span":{"begin":139,"end":143},"obj":"gene967"},{"id":"9736046-1#107#119#diseaseC0280100","span":{"begin":214,"end":226},"obj":"diseaseC0280100"}],"relations":[{"id":"16#20#gene3732107#119#diseaseC0280100","pred":"associated_with","subj":"9736046-1#16#20#gene3732","obj":"9736046-1#107#119#diseaseC0280100"},{"id":"26#31#gene967107#119#diseaseC0280100","pred":"associated_with","subj":"9736046-1#26#31#gene967","obj":"9736046-1#107#119#diseaseC0280100"},{"id":"32#36#gene967107#119#diseaseC0280100","pred":"associated_with","subj":"9736046-1#32#36#gene967","obj":"9736046-1#107#119#diseaseC0280100"}],"text":"Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.\nMRP-1/CD9, KAI1/CD82, and ME491/CD63, have been reported to be associated with the metastatic potential of solid tumors. The aim of this study was to determine whether their expression in tumor tissues is a useful indicator for prognosis in breast cancer patients. We studied 109 breast cancer patients who underwent surgery. Quantitative reverse transcription-polymerase chain reaction analysis was performed to evaluate the expression of these genes. The results were confirmed with immunohistochemistry. All of the carcinomas were ME491/CD63 positive. Thirty-six tumors were MRP-1/CD9 negative. The disease-free survival rate and the 5-year survival rate of patients with MRP-1/CD9-negative tumors were both significantly lower than that in patients with MRP-1/ CD9-positive tumors (P = 0.0005 and P = 0.0380, respectively). Sixty-five tumors were KAI1/CD82 negative. The disease-free survival rate of patients with KAI1/CD82-negative tumors was significantly lower than that of patients with KAI1/CD82-positive tumors (P = 0.0065). Cox regression analysis demonstrated that MRP-1/CD9 status (P = 0.0016) and KAI1/CD82 status (P = 0.0234) were useful indicators for the disease-free survival of breast cancer patients. The disease-free survival rate and 5-year survival rate of patients with either MRP-1/CD9-negative or KAI1/CD82-negative tumors were both significantly lower than patients who were positive for both genes (P = 0.0003 and P = 0.0292, respectively). The expression of MRP-1/CD9 and KAI1/CD82 genes are useful indicators of a poor prognosis in breast cancer patients."}

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":83,"end":89},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":348,"end":354},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":387,"end":393},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":1305,"end":1311},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":1670,"end":1676},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":301,"end":308},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.\nMRP-1/CD9, KAI1/CD82, and ME491/CD63, have been reported to be associated with the metastatic potential of solid tumors. The aim of this study was to determine whether their expression in tumor tissues is a useful indicator for prognosis in breast cancer patients. We studied 109 breast cancer patients who underwent surgery. Quantitative reverse transcription-polymerase chain reaction analysis was performed to evaluate the expression of these genes. The results were confirmed with immunohistochemistry. All of the carcinomas were ME491/CD63 positive. Thirty-six tumors were MRP-1/CD9 negative. The disease-free survival rate and the 5-year survival rate of patients with MRP-1/CD9-negative tumors were both significantly lower than that in patients with MRP-1/ CD9-positive tumors (P = 0.0005 and P = 0.0380, respectively). Sixty-five tumors were KAI1/CD82 negative. The disease-free survival rate of patients with KAI1/CD82-negative tumors was significantly lower than that of patients with KAI1/CD82-positive tumors (P = 0.0065). Cox regression analysis demonstrated that MRP-1/CD9 status (P = 0.0016) and KAI1/CD82 status (P = 0.0234) were useful indicators for the disease-free survival of breast cancer patients. The disease-free survival rate and 5-year survival rate of patients with either MRP-1/CD9-negative or KAI1/CD82-negative tumors were both significantly lower than patients who were positive for both genes (P = 0.0003 and P = 0.0292, respectively). The expression of MRP-1/CD9 and KAI1/CD82 genes are useful indicators of a poor prognosis in breast cancer patients."}

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T638","span":{"begin":1185,"end":1190},"obj":"gene:4363"},{"id":"T639","span":{"begin":1305,"end":1318},"obj":"disease:C0006142"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T638","obj":"T639"},{"id":"R2","pred":"associated_with","subj":"T638","obj":"T639"},{"id":"R3","pred":"associated_with","subj":"T638","obj":"T639"},{"id":"R4","pred":"associated_with","subj":"T638","obj":"T639"},{"id":"R5","pred":"associated_with","subj":"T638","obj":"T639"},{"id":"R6","pred":"associated_with","subj":"T638","obj":"T639"},{"id":"R7","pred":"associated_with","subj":"T638","obj":"T639"},{"id":"R8","pred":"associated_with","subj":"T638","obj":"T639"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.\nMRP-1/CD9, KAI1/CD82, and ME491/CD63, have been reported to be associated with the metastatic potential of solid tumors. The aim of this study was to determine whether their expression in tumor tissues is a useful indicator for prognosis in breast cancer patients. We studied 109 breast cancer patients who underwent surgery. Quantitative reverse transcription-polymerase chain reaction analysis was performed to evaluate the expression of these genes. The results were confirmed with immunohistochemistry. All of the carcinomas were ME491/CD63 positive. Thirty-six tumors were MRP-1/CD9 negative. The disease-free survival rate and the 5-year survival rate of patients with MRP-1/CD9-negative tumors were both significantly lower than that in patients with MRP-1/ CD9-positive tumors (P = 0.0005 and P = 0.0380, respectively). Sixty-five tumors were KAI1/CD82 negative. The disease-free survival rate of patients with KAI1/CD82-negative tumors was significantly lower than that of patients with KAI1/CD82-positive tumors (P = 0.0065). Cox regression analysis demonstrated that MRP-1/CD9 status (P = 0.0016) and KAI1/CD82 status (P = 0.0234) were useful indicators for the disease-free survival of breast cancer patients. The disease-free survival rate and 5-year survival rate of patients with either MRP-1/CD9-negative or KAI1/CD82-negative tumors were both significantly lower than patients who were positive for both genes (P = 0.0003 and P = 0.0292, respectively). The expression of MRP-1/CD9 and KAI1/CD82 genes are useful indicators of a poor prognosis in breast cancer patients."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":301,"end":308},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":83,"end":89},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":348,"end":354},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":387,"end":393},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":1305,"end":1311},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":1670,"end":1676},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.\nMRP-1/CD9, KAI1/CD82, and ME491/CD63, have been reported to be associated with the metastatic potential of solid tumors. The aim of this study was to determine whether their expression in tumor tissues is a useful indicator for prognosis in breast cancer patients. We studied 109 breast cancer patients who underwent surgery. Quantitative reverse transcription-polymerase chain reaction analysis was performed to evaluate the expression of these genes. The results were confirmed with immunohistochemistry. All of the carcinomas were ME491/CD63 positive. Thirty-six tumors were MRP-1/CD9 negative. The disease-free survival rate and the 5-year survival rate of patients with MRP-1/CD9-negative tumors were both significantly lower than that in patients with MRP-1/ CD9-positive tumors (P = 0.0005 and P = 0.0380, respectively). Sixty-five tumors were KAI1/CD82 negative. The disease-free survival rate of patients with KAI1/CD82-negative tumors was significantly lower than that of patients with KAI1/CD82-positive tumors (P = 0.0065). Cox regression analysis demonstrated that MRP-1/CD9 status (P = 0.0016) and KAI1/CD82 status (P = 0.0234) were useful indicators for the disease-free survival of breast cancer patients. The disease-free survival rate and 5-year survival rate of patients with either MRP-1/CD9-negative or KAI1/CD82-negative tumors were both significantly lower than patients who were positive for both genes (P = 0.0003 and P = 0.0292, respectively). The expression of MRP-1/CD9 and KAI1/CD82 genes are useful indicators of a poor prognosis in breast cancer patients."}